Agile Therapeutics, Inc. receives a Complete Response Letter from the FDA for Twirla (AG200-15) for the prevention of pregnancy. Agile Therapeutics, Inc., a women’s healthcare company, announced that the U.S. Food and Drug Administration (FDA) issued a complete response letter (CRL) in response to the New Drug Application (NDA) resubmission for the company’s investigational non-daily, low…